Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG

(EUZ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eckert & Ziegler Receives Approval for Gallium-68 Generator for Brasil

11/18/2021 | 07:20am EST

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Regulatory Approval/Expansion
Eckert & Ziegler Receives Approval for Gallium-68 Generator for Brasil

18.11.2021 / 13:18
The issuer is solely responsible for the content of this announcement.


Berlin, 18 November 2021. Eckert & Ziegler Radiopharma GmbH has received approval for its pharmaceutical 68Ge/68Ga generator GalliaPharm(R) from the Brazilian health authority ANVISA. GalliaPharm(R) is thus the first and currently the only pharmaceutical gallium generator approved in Brazil.

"The approval strengthens our market position in Brazil and marks another milestone in our expansion strategy", explains Dr. Lutz Helmke, Executive Director of Eckert & Ziegler AG and responsible for the Medical segment. "Since there are currently many clinical studies with so-called theranostics worldwide, we expect an increasing demand for both the diagnostic radioisotope gallium-68 and the therapeutic radioisotope lutetium-177 in the next few years".

GalliaPharm(R) is already successfully used in combination with approved kits, for the diagnosis of neuroendocrine tumors and in clinical trials also for prostate cancer (Ga-68-PSMA kit).

In Brazil, more than 590.000 new cases of cancer have been reported in 2020, with 97.278 in prostate, followed by breast (88.492) and colorectum cancer (55.102). (Source: IARC Global Cancer Observatory, 2020).

Gallium generators offer a low-cost alternative to radioactive labeling of biomolecules with gallium-68 in PET, an imaging examination method used to detect the presence or absence of diseased tissue. The procedure is used primarily in the diagnosis of cancer, heart attacks or neurological diseases. Up to now, the radioisotopes fluorine-18 or carbon-11 have mostly been used to label biomolecules. This requires millions of dollars of investment in large-scale equipment (cyclotrons). The 68Ge/68Ga generator, on the other hand, is about the size of a thermos flask and can be obtained much more cheaply, which reduces costs and increases flexibility in nuclear medical clinics and practices.

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

For further information or questions, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de



18.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1250274

 
End of News DGAP News Service

1250274  18.11.2021 

fncls.ssp?fn=show_t_gif&application_id=1250274&application_name=news&site_id=zonebourse_sftp

ę EQS 2021
All news about ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
01/11ECKERT & ZIEGLER STRAHLEN- UND MEDIZ : Notification and public disclosure of transactions ..
EQ
01/11Eckert & Ziegler Unit Enters Supply Deal for Ytterbium-176 Isotope with US Firm; Shares..
MT
01/10Eckert & Ziegler Signs Exclusive Supply Agreement for Ytterbium-176
EQ
01/03Eckert & Ziegler Buys Argentinian Nuclear Medicine Firm Tecnonuclear
MT
01/03???????Eckert & Ziegler Acquires Argentinian SPECT Specialist
EQ
01/03Eckert & Ziegler Strahlen- und Medizintechnik AG acquired Tecnonuclear S. A.
CI
2021Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIX..
EQ
2021ECKERT & ZIEGLER STRAHLEN UND MEDIZI : Declaration on the Corporate Governance Code 2021
PU
2021Eckert & Ziegler Receives Approval for Gallium-68 Generator for Brasil
EQ
2021Eckert & Ziegler Receives Approval for Gallium-68 Generator for Brasil
CI
More news
Analyst Recommendations on ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
More recommendations
Financials
Sales 2021 180 M 200 M 200 M
Net income 2021 26,9 M 30,0 M 30,0 M
Net cash 2021 96,9 M 108 M 108 M
P/E ratio 2021 56,6x
Yield 2021 0,59%
Capitalization 1 540 M 1 718 M 1 717 M
EV / Sales 2021 8,04x
EV / Sales 2022 6,29x
Nbr of Employees 841
Free-Float -
Chart ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Duration : Period :
Eckert & Ziegler Strahlen- und Medizintechnik AG Technical Analysis Chart | EUZ | DE0005659700 | MarketScreener
Technical analysis trends ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 74,20 €
Average target price 172,00 €
Spread / Average Target 132%
EPS Revisions
Managers and Directors
Andreas Eckert Chairman-Executive Board
Wolfgang Maennig Chairman-Supervisory Board
Helmut Grothe Vice Chairman-Supervisory Board
Albert Rupprecht Member-Supervisory Board
Edgar L÷ffler Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
ECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG-21.15%1 718
JOHNSON & JOHNSON-0.28%449 095
ROCHE HOLDING AG-6.46%307 637
PFIZER, INC.-9.62%299 559
ABBVIE INC.0.42%240 379
NOVO NORDISK A/S-12.29%219 960